SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,977,065 | -64.7% | 71,711 | -61.5% | 0.09% | -63.8% |
| Q2 2023 | $5,601,944 | +145.9% | 186,359 | +196.4% | 0.26% | +129.5% |
| Q1 2023 | $2,277,844 | +2.2% | 62,872 | +0.6% | 0.11% | -0.9% |
| Q4 2022 | $2,229,901 | +154.8% | 62,515 | +141.9% | 0.11% | +135.4% |
| Q3 2022 | $875,000 | -21.7% | 25,842 | -33.2% | 0.05% | -18.6% |
| Q2 2022 | $1,118,000 | -51.4% | 38,667 | -45.7% | 0.06% | -44.3% |
| Q1 2022 | $2,300,000 | +8.0% | 71,159 | -2.5% | 0.11% | +15.2% |
| Q4 2021 | $2,129,000 | +1.1% | 73,004 | -7.5% | 0.09% | -7.1% |
| Q3 2021 | $2,105,000 | -18.2% | 78,915 | -5.6% | 0.10% | -17.5% |
| Q2 2021 | $2,573,000 | +16.4% | 83,570 | -1.1% | 0.12% | +10.1% |
| Q1 2021 | $2,211,000 | -14.3% | 84,464 | -17.6% | 0.11% | -22.7% |
| Q4 2020 | $2,579,000 | -42.9% | 102,502 | -52.7% | 0.14% | -49.6% |
| Q3 2020 | $4,517,000 | +14.6% | 216,713 | +30.6% | 0.28% | +9.4% |
| Q2 2020 | $3,942,000 | – | 165,977 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |